---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-109437"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:34:29.411865+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kalaris reports positive Phase 1a TH103 data, $118M cash, net loss $43.4M in 2025

## Summary
- Phase 1a in nAMD showed mean 10-letter BCVA gain, 129µm CST improvement, ~95% intraretinal fluid reduction.
- TH103 plasma Cmax 27-51 fold lower than approved anti-VEGF agents; no DLTs or serious AEs observed.
- Cash, equivalents and marketable securities $118.0M as of Dec 31, 2025; funding into Q4 2027.
- Net loss $43.4M for 2025 vs $69.2M in 2024; R&D expense $30.8M, G&A $15.4M.
- Completed $50.0M oversubscribed private placement in Dec 2025; Phase 1b/2 preliminary data expected 1H 2027.

## SEC filing metadata
- accession: 0001193125-26-109437
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/0001193125-26-109437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/d124100d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-109437
- JSON: https://secwatch.observer/filing/0001193125-26-109437.json
- Plain text: https://secwatch.observer/filing/0001193125-26-109437.txt

## Key facts
- Earnings Releases
  Kalaris Therapeutics, Inc. reported the year ended December 31, 2025 results: net income net loss was $43.4 million.
  - Period: the year ended December 31, 2025
  - Net income: net loss was $43.4 million
  - Result: reported results
  source text: On March 17, 2026, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/0001193125-26-109437-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.